Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 2, 1998, Pages 165-170

  Guichard, Sylvie ^a   Chatelut, Etienne ^a,b   Lochon, Isabelle ^a   Bugat, Roland ^a,b   Mahjoubi, Mondher ^c   Canal, Pierre ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c SANOFI   (France)

Author keywords

Irinotecan; Pharmacokinetics

Indexed keywords

IRINOTECAN;

ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLONIC NEOPLASMS; FEMALE; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MICE; MICE, INBRED BALB C;

EID: 0031833542     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050801     Document Type: Article

References (27)

1. Floyd CE, Stirling CT, Cohn I (1966) Cancer of the colon, rectum and anus. Review of 1687 cases. Ann Surg 163: 829
2. Eisenberg B, DeCosse JJ, Harford F (1982) Carcinoma of the colon and rectum: the natural history reviewed in 1,704 patients. Cancer 49: 1131
3. Penna C, Nordlinger B (1996) Locoregional chemotherapy for adjuvant treatment of colorectal adenocarcinoma. Eur J Cancer 32A: 1117
4. Gastrointestinal Tumor Study Group (1985) Prolongation of the disease-free survival in surgically treated rectal carcinoma. N Engl J Med 312: 1465
5. Buyse M, Zeleniuk-Jacquotte A, Chalmers TC (1988) Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA 259: 3571
6. Speyer J (1985) The rationale behind intraperitoneal chemotherapy in gastrointestinal malignancies. Semin Oncol 12: 23
7. Rothenberg M, Eckardt JR, Kuhn JG, et al (1996) Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14: 1128
8. Rougier P, Bugat R, Douillard JY, et al (1997) Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients treated with fluorouracil-based chemotherapy. J Clin Oncol 15: 251
9. Gupta E, Lestingi TM, Mick R, Ramirez J, Yokes EE, Ratain MJ (1994) Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54: 3723
10. Rivory LP, Robert J (1995) Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol 36: 176
11. Rivory LP, Robert J (1994) Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. J Chromatogr 661: 133
12. Corbett TH, Griswold DP, Roberts BJ, Peckham JC, Schabel FM (1977) Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer 40: 2660
13. Howell SB, Chu BB, Wung WE, Metha BM, Mendelsohn J (1981) Long duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions. J Clin Invest 67: 1161
14. Jones SB, Colins JM, Myers CE (1981) High volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Res 41: 55
15. Howell SB, Pfeifle CL, Wung WE, et al (1982) Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 87: 845
16. Canal P, Bugat R, Rokoszak B, Berg D, Soula G, Roché H (1986) Pharmacokinetics and efficacy of iv and ip VM26 chemotherapy in mice bearing Krebs II ascitic tumors. Eur J Cancer Clin Oncol 22: 765
17. Speyer JL, Collins JM, Dedrick RL (1980) Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally in patients with ovarian cancer. Cancer Res 40: 567
18. Zimm S, Cleary SM, Lucas WE, et al (1987) Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide. Cancer Res 47: 1712
19. Howell SB, Pfeifle CE, Olshen RA (1984) Intraperitoneal chemotherapy with melphalan. Ann Intern Med 101: 14
20. Dedrick RL (1985) Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 12: 1
21. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51: 4187
22. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y (1994) Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86: 836
23. Kuwato Y, Furuta T, Aonuma M, Yasuoka M, Yokokura T, Matsumoto K (1991) Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 28: 192
24. Howell SB (1985) New approaches to drug delivery: intraperitoneal chemotherapy. In: Petersdorf R, Adams R, Braunwald E (eds) Update VII, Harrison's principles of internal medicine. MacGraw-Hill, New York, pp 93-108
25. Hsiang YE, Lihou MG, Liu LF (1989) Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077
26. Kaneda N, Nagata H, Furuta T, Yokokura T (1990) Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse [published erratum appears in Cancer Res 50: 4451]. Cancer Res 50: 1715
27. Tsuji T, Kaneda N, Kado K, Yokokura T, Yoshimoto T, Tsuru D (1991) CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobiodyn 14: 341